drugset / Trial / NCT07090499

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

NCT07090499 ↗

Phase 1 Recruiting 310 enrolled Pfizer
NaSequentialOpen-labelTreatment

Summary

The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs are anticancer drugs designed to stick to cancer cells and kill them. The study drug will be given to participants through a needle in a vein (intravenous infusion). This study includes multiple parts. In the first part of the study, there will be different groups of people receiving different doses of the study drug. The study may also test different schedules.

Timeline

Start
2025-08-20
Primary completion
2028-07-08
Completion
2029-07-08

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-08046876 Unknown — Intravenous